Lamivudine API

Name	Lamivudine
Chinese name	拉米夫定
Cas Number	134678-17-4
Source	India
Qualifications	USDMF/CEP/-/-/-

Lamivudine is a nucleoside reverse transcriptase inhibitor and a deoxycytidine analogue. It is a nucleoside antiviral drug developed by Glaxo Wellcome in Canada and was approved by the US FDA in 1995 Listed. Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate. It is the active form of lamivudine, which is not only an inhibitor of HBV polymerase, but also a substrate of this polymerase. Lamivudine has almost no effect on the DNA content of mammalian cells. Compared with α-interferon, lamivudine therapy has a wider range of indications, better curative effect, no need for intramuscular injection, less side effects, and relatively more affordable prices. The efficacy of lamivudine in the treatment of hepatitis B has been recognized globally, and it is currently the most effective and representative nucleoside analogue in clinical applications. Global sales in 2018 were 606 million yuan.

Hot Tags: lamivudine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Troxagliptin Succinate API, Canagliflozin API, Idebenone API, Ranolazine API, Teriflunomide API, Vardenafil API

• Previous: Ursodeoxycholic Acid API
• Next: Palonosetron Hydrochloride API